Podcasts about dipeptidyl

BUFFALO, NY- September 20, 2023 – A new editorial paper was published in Oncotarget's Volume 14 on September 15, 2023, entitled, “Potential repurposing of DPP4 inhibitors for target therapy resistance in renal cell carcinoma.” In their new editorial, researchers Kuniko Horie and Satoshi Inoue from Saitama Medical University and Tokyo Metropolitan Institute for Geriatrics and Gerontology discuss renal cell carcinoma (RCC) — a major adult kidney cancer, which is often incidentally discovered as an asymptomatic disease on imaging in the developed countries. RCC has the most fatal disease among urological cancers, as a recent 5-year relative survival rate in the U.S. (2009–2015) is less than 80%. While RCC is known as a cancer resistant to chemo- and radio-therapies, the prognosis of RCC has been remarkably improved after the clinical application of tyrosine kinase inhibitors (TKIs) and immunotherapy. The rationale for the efficacy of TKIs in RCC is mainly based on the angiogenetic status, particularly in clear cell RCC (ccRCC) that is the most common type of RCC (70–75% of RCC), in which the loss of function mutation of Von Hippel-Lindau (VHL) tumor suppressor gene activates hypoxia inducible factor (HIF) and vascular endothelial growth factor (VEGF) pathways. The first-line TKIs that predominantly target VEGF receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) (e.g., sunitinib and sorafenib) have been clinically used since late 2000s, and the second-line TKIs such as cabozantinib, which targets more receptor tyrosine kinases including MET and TAM kinases as well as VEGFR, have been further applied to the treatment of advanced RCC since early 2010s in which the first-line TKIs are ineffective. “In our recent study, we established a panel of patient-derived ccRCC spheroid cultures with the enhancement of cancer stemness gene signature including DPP4 [9]. Focusing on TKI sunitinib sensitivity, we demonstrated that DPP4 inhibition increased sunitinib efficacy in DPP4-high RCC spheroids and DPP4 was upregulated in sunitinib-resistant RCC cells.” DOI - https://doi.org/10.18632/oncotarget.28463 Correspondence to - Satoshi Inoue - sinoue07@gmail.com Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28463 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, renal cell carcinoma (RCC), tyrosine kinase inhibitor (TKI), Dipeptidyl peptidase IV (DPP4), drug resistance, drug repurposing About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Commentary by Dr Chung-Lieh Hung

Commentary by Dr. Douglas Mann

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.08.24.265033v1?rss=1 Authors: Silva-Garcia, M., Bolgi, O., Ross, B., Pilla, E., Vijayalakshmi, K., Killisch, M., Stark, N., Lenz, C., Spitzner, M., Gorrell, M. D., Grade, M., Urlaub, H., Dobbelstein, M., Huber, R., Geiss-Friedlander, R. Abstract: Dipeptidyl peptidase 9 (DPP9) is a serine protease cleaving N-terminal dipeptides preferentially post-proline with (patho)physiological roles in the immune system and cancer. Only few DPP9 substrates are known. Here we identify an association of human DPP9 with the tumour suppressor BRCA2, a key player in repair of DNA double-strand breaks that promotes the formation of RAD51 filaments. This interaction is triggered by DNA-damage and requires access to the DPP9 active-site. We present crystallographic structures documenting the N-terminal Met1-Pro2 of a BRCA21-40 peptide captured in the DPP9 active-site. Mechanistically, DPP9 targets BRCA2 for degradation by the N-degron pathway, and promotes RAD51 foci formation. Both processes are phenocopied by BRCA2 N-terminal truncation mutants, indicating that DPP9 regulates both stability and the cellular stoichiometric interactome of BRCA2. Consistently, DPP9-deprived cells are hypersensitive to DNA-damage. Together, we identify DPP9 as a regulator of BRCA2, providing a possible explanation for DPP9 involvement in cancer development. Copy rights belong to original authors. Visit the link for more info

Broad Spectrum Digestive Enzymes Children on the autism spectrum have difficulty digesting their food properly. This means they do not absorb the nutrients from the foods they eat. This starves their brain of what it needs to function properly. Broad spectrum enzymes assist in the digestion of many foods including protein, carbohydrates, fats, and fiber. Enzymes are naturally produced by the body unless the GI tract is not working properly. If so, digestion and absorption of nutrients and many other factors are effected. Enzymes can be very helpful when taken just before or with meals to help break down food particles, proteins, carbohydrates, and fats. The enzyme known as DPPIV helps break down the large proteins in wheat known as gluten, and casein in dairy. Enzymes for Therapeutic use When enzymes are taken away from food they can be helpful as little garbage collectors in the sense of cleaning up the toxic debris from various viral and bacterial issues. Benefits Beyond Digestion Enzymes can be extremely helpful with the sensitive digestion needs of those with autism, ADHD, allergies, and more. By improving digestion there can be a reduction in inflammation in the GI tract, therefore, better overall health. Keeping the gut healthy is crucial. The gut has receptors that make neurotransmitters for the brain such as serotonin which effects mood, appetite, and sleep, and GABA which acts to calm nerve function. Enzymes also act as little garbage collectors cleaning up toxic debris .   From using enzymes parents report better concentration, increased language abilities, improved digestion, and behavior.   Help with positive gut bacteria and phenols There are beneficial microorganisms in the gut that are built from fiber foods such as vegetables. If the GI tract is compromised and weak it can have trouble digesting fiber. Additionally, Phenols are a compound found in many healthy foods including vegetables and dark colored fruit. These are healthy foods but our kids may be sensitive to them. One enzyme formula that can be helpful with both fiber digestion and phenols is No-Phenol from Houston-Enzymes. They come in capsules and chewable form.    Some Common Enzymes are: • Dipeptidyl peptidase IV (DPP-IV) breaks down casomorphin (from casein) and gluteomorphins (from gluten) • Proteases break down proteins • Lactase breaks down lactose (found in dairy) • Amylase for starch (carbohydrate) digestion • Alpha-galactosidase breaks down beans and other fiber-rich foods • Xylanase helps digest fruits and vegetables (phenolic foods) • Beta-glucanase for fiber-rich vegetables and grains • Lipase breaks down lipids or fats • Bromelain and papain are enzymes derived from pineapple. They break down proteins. Note: Some people exhibit sensitivities to fruit or citrus, so watch for signs of this from your child. Cellulase may interfere with some time-released, cellulose-based medications. Ask your doctor or check your labels for hydroxypropyl cellulose, or hypromellose. Some products come as “cellulose-free”. Quality Products Broad spectrum digestive enzymes are taken just prior to eating a meal for their assistance in digestion. This helps the body absorb nutrients for better health and well being. There are several great products available such as Trienza by Houston-Enzymes.  This formula has the added benefit of DPP-IV, a specific enzyme that breaks down the larger proteins in dairy and wheat products that can injure the gut lining and create toxins in the blood which make their way to the brain. This often triggers an allergic response to these foods. Trienza also comes in a chewable form. The size of the meal often determines the dosage. Start slowly with half the recommended dosage and work your way up to the full amount over a 12-14 day period. The beauty of broad spectrum enzymes is that they assist with so many different types of foods. We do not always know exactly what disturbs our digestion. This way we cover a multitude of possibilities with one product. Radio Show interview Please listen to my radio show interview with Dr. Devon Houston of Houston-Enzymes. It is show #44. You can find it here. About Dr. Houston Devin Houston Ph.D. Incorporator and CEO of Houston Nutraceuticals Dr. Houston obtained a B.A. degree in Biology from Hendrix College in 1979. He then was awarded a B.S. degree in Medical Science in 1980 and a Ph.D. in Biochemistry from the University of South Alabama College of Medicine in 1987. Dr. Houston’s graduate work focused on how the aging process affected certain enzyme systems. Click Here for more details.

I've been getting a lot of questions lately about the mysterious molecule I consume before I eat bread and pasta - a compound that allows me to digest gluten without any of the "bathroom decommissioning" that so notoriously occurs after a hefty bout of gluten consumption. After all, I don't want to not eat bread or pasta for the rest of my life. I find them enjoyable. But due to glyphosate exposure from pesticides and herbicides, stress, a leaky gut and other modern assailants that make gluten a bigger issue than it ever has been in human history, I use a bit of better living through science to make gluten digestible. In today's podcast, I interview the inventors of Gluten Guardian - Matt Gallant and Wade Lightheart - the guys who first appeared in the podcast "" and later in my article "". Matt Gallant is an entrepreneur, a poker champion, an ex-rock guitarist, a serial entrepreneur (who's built 13 companies in the last 20 years) strength and conditioning coach with a degree in kinesiology, the CEO and co-founder of a company called BiOptimizers. Wade T. Lightheart, host of the AWESOME Health Podcast, 3-time All Natural National Bodybuilding Champion, advisor to the American Anti-Cancer Institute and Cofounder of BiOptimizers. He is also the author of several books including the best-selling books, “Staying Alive in a Toxic World” and “The Wealthy Backpacker.” MARGE LINK TO WADE'S BOOKS During our discussion, you'll discover: -Why Matt eats between 6-10,000 calories every Sunday...7.36 For the calorie spike. One meal per day for 6 days. A combo of healthy and regular food. Matt feels great afterwards. He takes the day off from training. -Why we should be cognizant of our gluten intake, even if we don't have celiac disease...10:30  New England Journal of Medicine listed 55 diseases that can be caused by eating gluten. Many times we're not aware of these diseases; can be immune, neurological and psychiatric. Differences between wheat germ in the gluten and gluten itself. Different type of protein. Both are resistant to digestion. Can make the gut more permeable. (Leaky gut) Amylase/trypsin inhibitors come packaged with gluten - specifically wheat. What about other factors to leaky gut such as stress and glyphosate. 4x increase in celiac disease; traced to glyphosate interrupting the digestive process. Will continue to increase due to the exposure to glyphosate.  -The use of enzymes in the preparation of food to increase its palatability...18:10 In a perfect world, you'd be eating pre-digested food primarily. You use enzymes to assist with breaking food down. -Do Matt and Wade recommend any panels for evaluating gluten sensitivity or gluten cross reactivity?...20:30 Anti-tissue trans glutaminase or endomysial antibody. Recommend Cyrex. Helps you know if other foods such as coffee or quinoa are exacerbating your level of gluten intolerance. Also testing gliad and peptide antibodies. How does gluten negatively affect the brain?...24:00 Inflames the brain by causing an auto-immune response. Antibodies intended to protect your body actually attack your body. During the digestive process, gluten can be broken down into proteins similar to psychedelic drugs. Has an addictive quality. Overloads the brain with glutamate. Irritates and damages brain cells. Negative impact on your social life. -What Wade REALLY thinks about Monsanto...29:50 They were written into protection against lawsuits by federal law during the previous administration. Demonstrable evidence of their products causing damage to the body. Has been bought out by Bayer. Food has essentially been mutated, much to our detriment. Destroy livelihoods of small farmers. -The product Matt uses to pre-digest gluten before you even eat it...37:00 Dipeptidyl peptidase 4, also DPP-4. Dissolves bread placed in water in 15 minutes (watch the video below) You take it while you eat. Does DPP-4 actually mitigate symptoms of gluten intolerance? Depends on the dosage. Can be taken as late as the day after eating. Citrusy foods have been found to inhibit DPP-4 Breaks down various hormones in the body such as insulin. -Does DPP-4 have any effect on foods not containing gluten?...45:00 Milk proteins, but not milk sugars like lactose. Good idea to add DPP-4 if you have a plant-based diet. Just mix and match until you find the right combination for you, and for the right meals. Safe for children to ingest. -More on Matt and Wade's diet and workout regimen...49:50 -How do HCL and hydrochloric acid work with Gluten Guardian?...54:55 Plays a supportive role Stomach acid decreases after the age of 35 Simulates the effects of apple cider vinegar P3-OM  Optimal time to take is before bed or first thing in the morning, rather than meal time. -Matt plays "myth busters" with colonizing properties of probiotics...58:41 -Special offer from Matt and Wade...1:04:15 Get 10% off your order of Gluten Guardian when you use code "greenfield" at 365 day unconditional money-back guarantee Brand new offer: "we'll fix your digestion guarantee" Resource from this episode: -Masszymes -Cyrex blood panel for gluten allergy -Book: Grain Brain Episode Sponsors: - utilizes sound waves to optimize sexual performance and reverse the effects of ED. Purchase 6 treatments, and get the 7th treatment for FREE. - Discover Omax3, the 93.9% pure omega-3 supplement developed by Yale-affiliated scientists. Use my link and you can try an entire box for FREE, plus get 60% off your first month's supply. - Organic brands you love, for less. Get your favorite Organic & Non-GMO brands delivered to your door! Get 25% off your first order when you use my link. - Make the cold your secret weapon with next-level cold gear. Enter code "ben" at checkout and receive 15% off your order! Do you have questions, thoughts or feedback for Matt, Wade or me? Leave your comments at http://bengreenfieldfitness.com/glutenpodcast and one of us will reply!

On this episode we're very grateful to have interviewed PhD candidate Devin Abrahami, the first author of the paper "Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study" published in the March 2018 issue of the British Medical Journal. This paper from the group of Dr. Laurent Azoulay really made a lot of waves in the medical community, achieving an Altmetric score of 320 and still climbing and is a must-read.

Hosts: Vincent Racaniello, Michele Swanson, and Michael Schmidt. Vincent, Michael, and Michele reveal how a fungal protease blunts the innate immune response and promotes pathogenicity. Subscribe to TWiM (free) on iTunes, Stitcher, RSS, or by email. You can also listen on your mobile device with the Microbeworld app. Links for this episode Michele on Flint Legionella outbreak (Detroit News) Fungal mimicry of a mammalian aminopeptidase (Cell Host Micr)   This episode is sponsored by ASM Agar Art Contest and ASM Microbe 2016 Send your microbiology questions and comments (email or mp3 file) to twim@twiv.tv, or call them in to 908-312-0760. You can also post articles that you would like us to discuss at microbeworld.org and tag them with twim.

Hosts: Vincent Racaniello, Alan Dove, and Kathy Spindler Vincent, Alan, Kathy, and Dickson discuss identification of a cell receptor for the coronavirus-EMC, and the role of interferon-epsilon in protecting the female reproductive tract. Links for this episode: Dipeptidyl peptidase 4 is CoV-EMC receptor (Nature) Receptor for new coronavirus (Nature) Broad reception for coronavirus (Nature) SARS 10th anniversary (Science) Interferon-epsilon protects female reproductive tract (Science) Families fighting flu (YouTube) Monitoring infections with online data (TWiM 41) Natalie Portman was a scientist (NY Times) Letters read on TWiV 223 Weekly Science Picks Kathy - 2013 Intel Science Talent Search awardsAlan - Krebs Cycle Rap (CDC)Vincent -  Jetpens (favorite one and two)D ickson - Rabies death in organ recipients (CDC) Listener Pick of the Week Justin - The DNA StoreJim - Massive Open Online ClassroomsChris - Feedly Send your virology questions and comments (email or mp3 file) to twiv@twiv.tv

Orally and intravenously administered glucose yields comparable levels of glucose in plasma but different responses of insulin-release. Specialised mucosa cells react to glucose contents in chyme with release of glucagon-like peptide-1 (GLP-1) into the portal bloodstream, a peptide hormone, that makes beta-cells more sensitive to the subsequent glucose stimulus and thereby enhances the insulin-release exclusively under increased blood glucose levels without causing the insulin-release directly. The capacity of this entero-insular axis is limited primarily by the endogenous enzyme dipeptidyl peptidase IV (DPP-IV). Prevailingly the most progressive approach to therapy of non-insulin-dependent diabetes mellitus (NIDDM) in human medicine is targeted on the inhibition of DPP-IV, in order to raise GLP-1 concentration in plasma and to increase consequently the insulin-release in dependence on elevated blood glucose levels. In the limelight of discussion are the advantages of certain avoidance of insulin-caused hypoglycaemia on the one hand and the possibility of oral administration of the antienzyme on the other hand. In contrast to the condition in dogs, where the disease manifests almost exclusively in the form of secondary (insulin-dependent) diabetes mellitus, the type 2 (NIDDM) predominates in humans as well as in cats, whence it comes that the employment of oral antidiabetics in the latter species is quite promising, as the experience with the sulfonyl urea derivative glipizide has shown. As however the residual capacity of beta-cells of feline diabetics with regard to the release of endogenous insulin is subject to considerable variation, the risk of inducing hypoglycaemia is given by use of both insulin and sulfonyl urea derivatives, whereas this threat is circumvented by use of DPP-IV-inhibitors. In the present thesis the effect of DPP-IV inhibition on the elimination kinetics of GLP-1 is described by means of systematically combined infusion of the enzyme’s substrate (GLP-1) and its antienzyme in the rat model. The maximum effective dose of DPP-IV inhibitor is determined and the portion of hepatic clearance and whole blood clearance of total elimination of GLP-1 without concurrent DPP-IV inhibition is quantified approximately by means of isolated perfused rat livers and in-vitro-experiments. Finally the dependence of results on the respective experimental design is demonstrated. The total clearance of GLP-1 as substrate of DPP-IV without concurrent inhibition amounts to at least 57 ± 17 (mL/min)/kg and under influence of the DPP-IV-inhibitor to at least 22 ± 2 (mL/min)/kg. The value of clearance is highly dependent on the respective substrate concentration in plasma, so that the values range from 139 ± 57 (mL/min)/kg to 73 ± 15 (mL/min)/kg within the bounds of physiological GLP-1 concentrations in plasma. The maximum increase of GLP-1 levels in plasma (factor 3.4) on average of all GLP-1 infusion rates was attained by a DPP-IV inhibitor concentration in plasma of 0.4 µmol/L. The liver as central detoxication-organ figures out at 57 % (34/60) of total clearance, the soluble DPP-IV fraction in plasma however accounts for only about 1 % (0.7/60) of total clearance. The relatively low hepatic extraction ratio of 30 ± 11 % reversely allows seven out of ten GLP-1 molecules to enter the systemic circulation in spite of the first-pass-effect and thereby to reach possibly the receptors on the beta-cells (70 % bioavailability). The half-life of GLP-1 (7-36 amide) in the isolated perfused rat liver amounts to 5.0 ± 1.3 minutes, hereby differing statistically not significantly (p = 0.114) from the half-life of GLP-1 (7-37) with 6.1 ± 1.6 minutes.